| Title | [Comment on the Cochrane analysis >>Dopamine agonist therapy in early Parkinson's disease<<] | | Author(s) | Bode M | | Institution | Neurologisk Afdeling, Odense Universitetshospital, DK-5000 Odense C. matthias.bode@ouh.regionsyddanmark.dk. | | Source | Ugeskr Laeger 2009 Oct 5; 171(41):2996-2999. | | Abstract | The Cochrane analysis confirms some well-known facts: initial therapy with dopamine agonists (DA) delays the incidence of motor complications, but is associated with inferior motor control and a higher frequency of non-motor adverse events (AE) compared with levodopa. Some serious AE are missing, probably due to the design of the included studies. The results will not change current treatment guidelines, but they emphasize the need for >>real-life<< studies with patients' quality of life or economic parameters as primary outcomes. | | Language | DAN | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19814927 |
|
